Medtronic Plc (NYSE:MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. The ...

Medtronic PLC (MDT) reports robust revenue and EPS growth, driven by innovations in Cardiac Ablation and Leadless Pacing, ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

Q3 2025 Earnings Call Transcript February 18, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.39, ...

Reports Q3 revenue $8.29B, consensus $8.33B. “We delivered strong earnings this quarter, with significant improvements in both our gross margin ...

The medical device company posted revenue of $8.29 billion in the period, falling short of Street forecasts. Ten analysts surveyed by Zacks expected $8.33 billion. Medtronic expects full-year earnings ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

Medtronic's Q3 adjusted EPS of $1.39 surpassed forecasts by $0.03. Revenue of $8.29 billion fell short of expectations by $40 million. Premarket trading saw a 4.48% drop in Medtronic's stock price.

Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.